KLK4 and COVID-19: Since the kinin-kallikrein system plays a role in the pathophysiology of ALI, we hypothesize that EVs carrying kininogen-1 may enter the bloodstream, contribute to systemic inflammation, and consequently increase the risk for thrombosis in COVID-19.